NYSEMKT: APUS
Apimeds Pharmaceuticals Us Inc Stock Ownership - Who owns Apimeds Pharmaceuticals Us?

Insider buying vs selling

Have Apimeds Pharmaceuticals Us Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when APUS insiders and whales buy or sell their stock.

APUS Shareholders

What type of owners hold Apimeds Pharmaceuticals Us Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Inscobee Inc384.41%5,801,234$15.66MInsider
Erik C. Emerson49.70%750,000$2.03MInsider
Jakap Koo42.67%643,885$1.74MInsider
Christopher Kim18.39%277,500$749.25kInsider
Hemenway Trust Co LLC0.02%274$739.80Institution
Hemenw0.02%274$739.80Institution
Vangrd0.00%64$172.80Institution
Vanguard Capital Management LLC0.00%63$170.10Institution
Geode Capital Management LLC0.00%35$94.50Institution
Geodec0.00%35$94.50Institution

1 of 2

APUS vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APUS0.01%99.99%
YCBD0.00%100.00%Net Selling
GELS0.00%13.37%
KALA0.00%100.00%
SNOA0.00%80.01%

Apimeds Pharmaceuticals Us Stock Ownership FAQ

Who owns Apimeds Pharmaceuticals Us?

Apimeds Pharmaceuticals Us (NYSEMKT: APUS) is owned by 0.03% institutional shareholders, 495.16% Apimeds Pharmaceuticals Us insiders, and 0.00% retail investors. Inscobee Inc is the largest individual Apimeds Pharmaceuticals Us shareholder, owning 5.80M shares representing 384.41% of the company. Inscobee Inc's Apimeds Pharmaceuticals Us shares are currently valued at $15.61M.

If you're new to stock investing, here's how to buy Apimeds Pharmaceuticals Us stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.